Profusa Inc. stocks have been trading up by 94.26 percent, likely driven by highly favorable sentiment from recent coverage
Key Takeaways
- Shares of PFSA dropped about 18% after Profusa signed a non-binding term sheet for a new acquisition.
- The targeted business is a privately held, commercial-stage diagnostics and toxicology testing company, already generating revenue.
- Because the Profusa acquisition term sheet is non-binding, there is no guarantee the PFSA deal will close as outlined.
- The sharp PFSA selloff signals trader concern about dilution, financing needs, and integration risk around Profusa’s planned expansion.
Live Update At 09:18:17 EDT: On Tuesday, August 18, 2026 Profusa Inc. stock [NASDAQ: PFSA] is trending up by 94.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
PFSA is trading like a classic high-risk, story-driven small cap. The recent daily chart shows Profusa closing at $4.53 on 2026/08/17 after a wild range between $3.75 and $6.77. Just days earlier, PFSA was stuck under $1, grinding between roughly $0.86 and $1.06. That kind of multi-bagger move followed by a sharp fade is the definition of a momentum rollercoaster.
Intraday, the 5-minute chart paints the same picture. Profusa spiked as high as the low $12s in the premarket before sliding back under $9 later in the morning. Volatility is extreme. For short-term traders, PFSA is all about timing and discipline, not comfort.
More Breaking News
On the fundamentals, Profusa is deep in the red. PFSA reported Q1 2026 net income of about -$3.46M and operating cash flow of roughly -$2.6M. Free cash flow came in near -$2.61M, while cash on hand was only about $375,000 at quarter end. With negative equity around -$28.2M and current liabilities far above current assets, Profusa is financially stretched. That backdrop matters when PFSA announces any acquisition plan.
Why Traders Are Watching PFSA Now
Profusa is back on every small-cap scanner because PFSA dropped 18% after announcing a non-binding term sheet to buy a privately held, commercial-stage diagnostics and toxicology testing company. On paper, that kind of target sounds attractive. The business is already commercial, which means real products and likely real revenue. Strategically, it could give Profusa a faster path to market and broaden PFSA’s footprint in diagnostics.
But traders did not cheer. They sold. That immediate 18% hit tells you how the market reads this move: more risk before any clear reward. For many PFSA traders, the first questions are simple. How will Profusa pay for this? Will there be equity raises, debt, or both? With negative working capital and limited cash, PFSA does not have much room to maneuver without tapping markets again.
The non-binding nature of the term sheet adds another layer. Nothing is final. Terms can change, timelines can slip, or the deal can fall apart. That uncertainty alone can pressure PFSA, especially after such a big pre-news run. Short sellers see that and step in. Momentum longs see it and start locking in profits.
At the same time, this is exactly the setup active traders hunt: high volume, clear news catalyst, emotional reaction, and big intraday ranges. Profusa has become a textbook case in how deal headlines can flip sentiment fast. The key for PFSA traders now is tracking whether the stock stabilizes around new support or keeps bleeding as doubts grow about Profusa’s acquisition path.
Conclusion
PFSA is a reminder that Wall Street rarely gives free passes to cash-hungry companies announcing new deals. Profusa wants to buy a commercial-stage diagnostics and toxicology testing business, which, strategically, could help PFSA pivot into a more diversified, revenue-focused story. But the market’s first reaction was to hammer Profusa shares, not reward the ambition.
For short-term traders, that 18% drop is both a warning and an opportunity. PFSA shows massive volatility, thin margins for error, and a balance sheet that leaves little cushion if the Profusa acquisition drags on or requires heavy financing. Any PFSA bounce from here will likely be driven by technicals, short covering, and fresh headlines about how Profusa plans to structure the deal.
This is where discipline separates pros from gamblers. In the words often repeated by Tim Sykes, “Cut losses quickly; small losses are the cost of doing business in trading.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. That mindset fits PFSA perfectly. Profusa is a high-risk, catalyst-driven play. Traders studying PFSA need to respect the downside, follow the news on the non-binding term sheet, and treat every trade as an educational, research-driven decision — not a promise of profit.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply